Drug Trial Radar · NCT07142044
Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP Study)
Last checked: Nov 19, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Nov 1, 2025
Primary completion
Dec 2026
Study completion Jun 2027
Sponsor
- Lead sponsor
- EicOsis Human Health Inc.Industry
- Sponsor type
- Industry
- Collaborators
- University of California, Davis; Michael J. Fox Foundation for Parkinson's Research
- First posted
- Aug 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if the oral drug candidate EC5026 is safe and targets the correct pathways to treat Parkinson's Disease in adults. It will also learn about the levels of drug that are achieved in blood and in the fluid surrounding the brain (spinal fluid). The main questions it aims to answer are: * Is EC5026 safe in adults with Parkinson's Disease? * What are the levels of EC5026 achieved after oral administration for 28 days? * What molecules or pathways does EC5026 target, and to what extent? In addition, although it is not one of the primary aims of the study, this clinical trial will also explore if oral administration of EC5026 improves the symptoms of Parkinson's Disease. Researchers will compare EC5026 to a placebo (a look-alike substance that contains no drug). Participants will: * Take EC5026 or a placebo every day for 28 consecutive days * Visit the clinic for frequent checkups, blood tests, spinal fluid tests, and questionnaires
Conditions
- Parkinson's Disease (PD)
Interventions
EC5026 oral tabletDrug
Oral soluble epoxide hydrolase inhibitor
PlaceboDrug
Matching oral placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AEs) and Serious Adverse Events (SAE) [Safety and Tolerability]Time frame: 56 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of California Davis
Sacramento, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.